Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lyon – page 25

1 204 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lyon at a glance
1 204
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 204 trials in Lyon

Open in trial search

Hepatocellular carcinoma

Recruiting

Study of tislelizumab immunotherapy in patients with liver cancer (hepatocellular carcinoma) who have moderately impaired liver function (Child-Pugh B)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:Unicancer

Uveitis+1

Recruiting

Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Gastrointestinal stromal tumour

Recruiting

Study on Continuing or Stopping Imatinib in Patients with Advanced or Metastatic Gastrointestinal Stromal Tumors After 10 Years of Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Centre Leon Berard

Asthma

Recruiting

Study on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Colorectal cancer metastatic+2

Recruiting

Study on the Effects of Atezolizumab, Bevacizumab, Oxaliplatin, and Capecitabine in Patients with Colorectal Cancer and Liver Metastasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Primary biliary cholangitis

Recruiting

Study on Bezafibrate for Patients with Primary Biliary Cholangitis Not Responding Well to Ursodeoxycholic Acid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer metastatic

Recruiting

Study on the Safety and Effects of STX-241 for Patients with Advanced Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:STX-241
  • Sponsor:Pierre Fabre Medicament

Retinoblastoma

Recruiting

Study on Retinoblastoma Treatment Using Etoposide, Carboplatin, and Melphalan for Patients with Specific Eye Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

HER2 gene amplification

Recruiting

Study of zongertinib tablets in patients with advanced solid tumors that have HER2 gene changes

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zongertinib
  • Sponsor:Boehringer Ingelheim Espana S.A.

IgA nephropathy

Recruiting

Study on the Effect of Hydroxychloroquine for Patients with IgA Nephropathy and High Albumin Levels

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxychloroquine Sulfate
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Glomerulonephritis acute

Recruiting

Study of personalized rituximab dosing using artificial intelligence in patients with membranous nephropathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire De Nice

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

  • Triple-negative breast cancer treatments
  • Gastric and esophageal cancer therapies
  • Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

  • Novel COVID-19 intranasal vaccine development
  • Yellow fever vaccine studies
  • ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

  • Chronic kidney disease management
  • Heart failure prevention
  • Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.